Emergent BioSolutions, Inc. (NYSE: EBS)

Emergent BioSolutions, Inc. (NYSE: EBS), a leading biopharmaceutical company, is focused on its mission to protect life. To achieve this goal, the company develops, manufactures, and commercializes immune related biologics, vaccines and biotherapeutics designed to support the body’s immune system to prevent or treat infectious and other life threatening diseases. Their broad product pipeline also includes: two “next generation” anthrax vaccines, two anthrax therapeutics (immunoglobulin and monoclonal), two botulinum vaccines and a botulinum therapeutic, an oral typhoid vaccine, a next generation tuberculosis vaccine, a hepatitis B immunotherapy, and a chlamydia vaccine. For further information, visit the Company’s web site at www.ebsi.com.